Plerixafor (mozobil®) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation Journal Article


Authors: Flomenberg, N.; Comenzo, R. L.; Badel, K.; Calandra, G.
Article Title: Plerixafor (mozobil®) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation
Abstract: Rapid and durable recovery of hematopoietic function after hematopoietic stem cell transplantation (HSCT) requires the infusion of a sufficient number of hematopoietic stem cells (HSC). Granulocyte colony-stimulating factor (G-CSF), either alone or with chemotherapy, has been the traditional backbone of regimens used to mobilize HSC. Plerixafor (previously known as AMD3100), a selective antagonist of CXCR4, has recently been approved for autologous HSC mobilization in combination with G-CSF. The current study assessed the safety and efficacy of plerixafor as a single agent when given subcutaneously and followed by apheresis 6 hours later for the mobilization of HSC for transplantation in 9 patients with multiple myeloma (MM). All patients mobilized enough cells for at least 1 transplant, and demonstrated prompt recovery of hematopoietic function. Median time to engraftment was 10.5 days for neutrophils and 21 days for platelets. Significant adverse events were not observed. Recovery of peripheral blood cell counts was durable in all surviving patients. Despite these successes, mobilization with plerixafor alone was modest. However, in clinical circumstances where G-CSF or chemotherapy based-mobilization should not be used, mobilization with plerixafor alone may be required and effective. Further research into single agent use should focus on alternate route of administration as well as adjustment of the timing of the apheresis to improve cell HSC yield (ClinicalTrials.gov registration number: NCT00396383). © 2010 American Society for Blood and Marrow Transplantation.
Keywords: adolescent; adult; clinical article; aged; young adult; human cell; clinical trial; drug efficacy; drug safety; monotherapy; methodology; multiple myeloma; thrombocyte; hematopoietic stem cell transplantation; injection site reaction; drug fatality; drug induced headache; drug antagonism; engraftment; neutrophil; kinetics; multicenter study; stem cell mobilization; hematopoiesis; blood cell count; graft survival; granulocyte colony stimulating factor; gastrointestinal disease; granulocyte colony-stimulating factor; plerixafor; blood component removal; hematopoietic stem cell mobilization; heterocyclic compounds; transplantation, autologous; heterocyclic compound; autologous hematopoietic stem cell transplantation; receptors, cxcr4; chemokine receptor cxcr4; amd3100; autologous transplantation; apheresis; oral paresthesia; autotransplantation
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 16
Issue: 5
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2010-05-01
Start Page: 695
End Page: 700
Language: English
DOI: 10.1016/j.bbmt.2009.12.538
PUBMED: 20067838
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 20 April 2011" - "CODEN: BBMTF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raymond L Comenzo
    115 Comenzo